title: A therapeutic dendritic cell-based vaccine for HIV-1 infection.
abstract: A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.
authors.affiliation: Infectious Diseases Department, Hospital Clinic - HIV Development Program in Catalonia, Institut d'Investigacions Biomédiques August Pi I Sunyer, University of Barcelona, Spain. fgarcia@clinic.ub.es
authors.forename: Felipe
authors.initials: F
authors.lastname: García
authors.forename: Núria
authors.initials: N
authors.lastname: Climent
authors.forename: Lambert
authors.initials: L
authors.lastname: Assoumou
authors.forename: Cristina
authors.initials: C
authors.lastname: Gil
authors.forename: Nuria
authors.initials: N
authors.lastname: González
authors.forename: José
authors.initials: J
authors.lastname: Alcamí
authors.forename: Agathe
authors.initials: A
authors.lastname: León
authors.forename: Joan
authors.initials: J
authors.lastname: Romeu
authors.forename: Judith
authors.initials: J
authors.lastname: Dalmau
authors.forename: Javier
authors.initials: J
authors.lastname: Martínez-Picado
authors.forename: Jeff
authors.initials: J
authors.lastname: Lifson
authors.forename: Brigitte
authors.initials: B
authors.lastname: Autran
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.forename: Josep M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Montserrat
authors.initials: M
authors.lastname: Plana
authors.forename: Teresa
authors.initials: T
authors.lastname: Gallart
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D003713:Dendritic Cells / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D012367:RNA, Viral